Get the Stockscreener App
992.06
1.60%
-18.25
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $992.06, with a volume of 1.21M.
It is down -1.60% in the last 24 hours and up +7.55% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,010.31
Open:
$1010.74
24h Volume:
1.21M
Relative Volume:
0.32
Market Cap:
$887.22B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
49.06
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-6.02%
1M Performance:
+7.55%
6M Performance:
+29.14%
1Y Performance:
+20.26%
1-Day Range:
$988.88
$1,014.20
1-Week Range:
$988.88
$1,068.18
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
991.29 | 904.25B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.03 | 486.51B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.88 | 399.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.91 | 253.59B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.08 | 247.51B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Carolyn Bertozzi to Rejoin Eli Lilly (LLY) Board in December 202 - GuruFocus
Nobel laureate Carolyn Bertozzi returns to Eli Lilly board By Investing.com - Investing.com Canada
Nobel laureate Carolyn Bertozzi rejoins Eli Lilly board - StreetInsider
Carolyn Bertozzi returns to Lilly board of directors - WV News
As Lilly And Novo Nordisk Grow Their Obesity Empires, What Comes Next? - Citeline News & Insights
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term - Yahoo Finance
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump - 24/7 Wall St.
Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance - International Business Times
Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $1,145 From $951, Maintains Buy Rating - marketscreener.com
Eli Lilly's (LLY) Diabetes Drug Mounjaro Gains Access to China's Insurance Program - GuruFocus
Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog - marketscreener.com
‘A new day’: IU LAB chief talks $40M research agreement with Lilly - Inside INdiana Business
Eli Lilly’s Mounjaro to join China’s state health insurance scheme By Investing.com - Investing.com South Africa
Eli Lilly reports Phase III trial results of Jaypirca for CLL/SLL - Clinical Trials Arena
Eli Lilly Hit $1 Trillion and Still Can’t Get into the Dow - Disruption Banking
Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment - Reuters
Eli Lilly Scores Huge Win As China Adds Mounjaro To National Insurance — But Raises Fears Of A Brutal Pricing War - Benzinga
Eli Lilly obtains subsidy coverage for diabetes drug in China - medwatch.com
Eli Lilly Jaypirca met its primary endpoint in head-to-head Phase 3 study versus Imbruvica - Medical Dialogues
Eli Lilly (LLY) Gains with Key Drug Additions to China's Insuran - GuruFocus
Eli Lilly’s Strategic Momentum: Clinical Triumph and Analyst Confidence Fuel Growth - AD HOC NEWS
Jim Cramer Prefers Buying Eli Lilly When People Are "Getting Antsy" - Finviz
Eli Lilly, Pfizer drugs added to China's state insurance list (LLY:NYSE) - Seeking Alpha
Jim Cramer Prefers Buying Eli Lilly When People Are “Getting Antsy” - Insider Monkey
Eli Lilly, Pfizer Land on China’s First Private Insurance List - Bloomberg.com
Eli Lilly (LLY) Reports Positive Results from Jaypirca Phase 3 T - GuruFocus
Eli Lilly announces Phase 3 BRUIN CLL-314 met primary endpoint - TipRanks
Lilly’s Jaypirca shows higher response rate than Imbruvica in leukemia study - Investing.com Nigeria
Lilly's Jaypirca met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica - Investing News Network
Lilly’s Jaypirca shows higher response rate than Imbruvica in leukemia study By Investing.com - Investing.com South Africa
Lilly's Jaypirca met primary endpoint in head-to-head phase 3 study versus Imbruvica - marketscreener.com
Lilly (NYSE: LLY) Jaypirca shows up to 76% lower CLL progression risk vs Imbruvica - Stock Titan
At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma - BioPharma Dive
How Eli Lilly is Tackling Health Literacy and Sustainability - Healthcare Digital
Eli Lilly, Pfizer land on China’s first private insurance list - BusinessLine
Eli Lilly, Pfizer Secure Inclusion in Chinese Private Health Insurance Catalog - marketscreener.com
Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip? - MSN
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip? - AOL.com
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip? - The Motley Fool
Lilly, IU Expanding Clinical Trial Access, Latest Treatments For Hoosiers - InkFreeNews.com
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Is It Too Late To Consider Eli Lilly After Its Massive Multi Year Share Price Surge - simplywall.st
Eli Lilly Among 4 Medical Newcomers To IBD Top Growth Stock Lists - Investor's Business Daily
With Eli Lilly Stock Sliding, Have You Assessed The Risk? - Trefis
Eli Lilly shares fell for seven consecutive sessions - MSN
A look into Eli Lilly’s sustainability efforts and what it suggests about the trend in Big Pharma - Healthcare Brew
Eli Lilly doctor explains how weight-loss medication Zepbound works - Fox 59
Eli Lilly Stock Hit A New Record High On Its Trump Deal; Is LLY Stock A Buy? - Investor's Business Daily
Eli Lilly, Indiana University enter $40 million clinical trial agreement - 95.3 MNC
Eli Lilly's Options Frenzy: What You Need to Know - Benzinga
Eli Lilly lowers price of Zepbound single-dose vials - Drug Store News
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):